TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial.
Clin Cancer ResSep 1, 2026
Cheng Xu, Si-Yang Wang, Man Nie et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II multicenter trial evaluated the efficacy and safety of TQB2618 plus penpulimab in recurrent/metastatic nasopharyngeal carcinoma. In the treatment-naïve cohort (TPGC), the objective response rate was 86.2%, with a median progression-free survival (PFS) of 10.8 months. The chemotherapy-free regimen (TP cohort) showed limited efficacy, with a median PFS of 1.6 months.
Key findings
- In the TPGC cohort, the objective response rate was 86.2%, including 4 complete responses.
- The median PFS in the TPGC cohort was 10.8 months, with a 12-month rate of 40.9%.
- No dose-limiting toxicities were observed in the TP cohort.
- Grade 3 to 4 treatment-related adverse events occurred in 83.3% of patients in the TPGC cohort.
Why it matters
The findings suggest that TQB2618 combined with chemotherapy may offer significant antitumor activity in treatment-naïve patients with nasopharyngeal carcinoma, while the dual immunotherapy alone has limited efficacy in those previously treated with PD-1 blockade.